Hepatitis D - Pipeline Review, H2 2017

  • ID: 4419020
  • Report
  • 64 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • F. Hoffmann-La Roche Ltd
  • Globeimmune Inc
  • Merck & Co Inc
  • Replicor Inc
  • Rodos BioTarget GmbH
  • SomaGenics Inc
  • MORE
Hepatitis D - Pipeline Review, H2 2017

Summary

The latest Pharmaceutical and Healthcare disease pipeline guide Hepatitis D - Pipeline Review, H2 2017, provides an overview of the Hepatitis D (Infectious Disease) pipeline landscape.

Hepatitis D, also known as the delta virus, is an infection that causes liver to swell. It is caused by the hepatitis D virus (HDV). Symptoms include yellowing of skin and eyes, joint pain, abdominal pains, vomiting, loss of appetite and fatigue. Risk factors include receiving many blood transfusions, abusing intravenous (IV) or injection drugs and being infected while pregnant.

Report Highlights

The latest Pharmaceutical and Healthcare latest pipeline guide Hepatitis D - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Hepatitis D (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hepatitis D (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Hepatitis D and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 4, 4 and 1 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Hepatitis D (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hepatitis D (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Hepatitis D (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hepatitis D (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hepatitis D (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hepatitis D (Infectious Disease)
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hepatitis D (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hepatitis D (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • F. Hoffmann-La Roche Ltd
  • Globeimmune Inc
  • Merck & Co Inc
  • Replicor Inc
  • Rodos BioTarget GmbH
  • SomaGenics Inc
  • MORE
Introduction

Hepatitis D - Overview

Hepatitis D - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Hepatitis D - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Hepatitis D - Companies Involved in Therapeutics Development

Alnylam Pharmaceuticals Inc

Eiger BioPharmaceuticals Inc

F. Hoffmann-La Roche Ltd

Globeimmune Inc

Merck & Co Inc

Replicor Inc

Rodos BioTarget GmbH

SomaGenics Inc

Hepatitis D - Drug Profiles

ALN-HDV - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GI-18000 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lonafarnib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Myrcludex-B - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

peginterferon alfa-2a - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

peginterferon lambda-1a - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RBT-05 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

REP-2139 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

REP-2165 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RNAi Oligonucleotide for Hepatitis D - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

vanitaracin A - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Hepatitis D - Dormant Projects

Hepatitis D - Discontinued Products

Hepatitis D - Product Development Milestones

Featured News & Press Releases

Oct 04, 2017: MYR GmbH Announces Presentation of Interim Results of Phase 2b Clinical Program of Myrcludex B at the American Association for the Study of Liver Diseases Conference

Sep 28, 2017: Replicor Announces Publication of its REP 301 Study in HBV / HDV Co-Infection in The Lancet Gastroenterology & Hepatology

Sep 05, 2017: Eiger Announces FDA Orphan Drug Designation Granted for Pegylated Interferon Lambda in Hepatitis Delta Virus Infection

Jul 27, 2017: Eiger Announces FDA Fast Track Designation Granted for Pegylated Interferon Lambda in Hepatitis Delta Virus Infection

Jul 24, 2017: Eiger Completes Enrollment in Phase 2 LIMT HDV Study of Pegylated Interferon Lambda in Hepatitis Delta Virus Infection

May 25, 2017: Hepatera: Eligibility to PRIME Scheme Granted to Myrcludex B by the European Medicines Agency

May 03, 2017: Eiger Announces U.S. IND Filing of Pegylated Interferon Lambda for Hepatitis Delta Virus Infection - LIMT HDV: Lambda Interferon MonoTherapy in HDV Study Enrolling

Apr 21, 2017: Eiger Announces Additional Phase 2 Clinical Trial Results for Lonafarnib at The International Liver Congress

Apr 06, 2017: Eiger Announces Abstracts and Presentations of LOWR HDV Program at the European Association for the Study of the Liver (EASL) Meeting

Apr 04, 2017: Maxwell Biotech Venture Fund's Portfolio Company Hepatera Announces Completion of Recruitment for Phase 2b Clinical Trials of Myrcludex B in Chronic Hepatitis Delta

Feb 20, 2017: Replicor discloses high rates of HBsAg loss with NAP combination therapy at APASL

Nov 15, 2016: Replicor Discloses Late Breaking HBV and Follow-Up HBV / HDV Clinical Data at AASLD

Nov 14, 2016: Eiger Announces Positive Phase 2 Data at the American Association for the Study of Liver Diseases (AASLD) Meeting

Oct 19, 2016: Eiger Announces First Patient Dosed in Phase 2 Study of Pegylated Interferon Lambda in Hepatitis D Virus Infection

Oct 13, 2016: Eiger Announces Abstracts and Presentations of LOWR HDV Program at the American Association for the Study of Liver Diseases (AASLD) Meeting

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Hepatitis D, H2

Number of Products under Development by Companies, H2

Number of Products under Development by Universities/Institutes, H2

Products under Development by Companies, H2

Products under Development by Universities/Institutes, H2

Number of Products by Stage and Target, H2

Number of Products by Stage and Mechanism of Action, H2

Number of Products by Stage and Route of Administration, H2

Number of Products by Stage and Molecule Type, H2

Hepatitis D - Pipeline by Alnylam Pharmaceuticals Inc, H2

Hepatitis D - Pipeline by Eiger BioPharmaceuticals Inc, H2

Hepatitis D - Pipeline by F. Hoffmann-La Roche Ltd, H2

Hepatitis D - Pipeline by Globeimmune Inc, H2

Hepatitis D - Pipeline by Merck & Co Inc, H2

Hepatitis D - Pipeline by Replicor Inc, H2

Hepatitis D - Pipeline by Rodos BioTarget GmbH, H2

Hepatitis D - Pipeline by SomaGenics Inc, H2

Hepatitis D - Dormant Projects, H2

Hepatitis D - Discontinued Products, H2

List of Figures

Number of Products under Development for Hepatitis D, H2

Number of Products under Development by Companies, H2

Number of Products by Targets, H2

Number of Products by Stage and Targets, H2

Number of Products by Mechanism of Actions, H2

Number of Products by Stage and Mechanism of Actions, H2

Number of Products by Routes of Administration, H2

Number of Products by Stage and Routes of Administration, H2

Number of Products by Molecule Types, H2

Number of Products by Stage and Molecule Types, H
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Alnylam Pharmaceuticals Inc
  • Eiger BioPharmaceuticals Inc
  • F. Hoffmann-La Roche Ltd
  • Globeimmune Inc
  • Merck & Co Inc
  • Replicor Inc
  • Rodos BioTarget GmbH
  • SomaGenics Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll